Formulary

How COVID-19 Is Affecting Those with Opioid Use Disorder

December 02, 2020

As the world remains battling the coronavirus pandemic, there are still significant and unmet needs for those fighting chronic conditions and disorders like opioid use disorder (OUD).

FDA Updates: Approvals in Rare Disorders; Expanded Approval for Flu Treatment

November 29, 2020

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Insurers Take up Mantle to Ensure Immunizations

November 23, 2020

Health plans build strategies to ensure their beneficiaries have easy access to and receive vital immunizations.

COVID-19 Updates: Trump Adviser Says Vaccines Could Ship Quickly; FDA Grants Emergency Use for Regeneron Cocktail

November 22, 2020

If Pfizer's vaccine gets an emergency use authorization, it could reach sites designated by states within a day.

FDA Updates: Alkermes Gets CRL on Manufacturing Issues; Missed Deadline on Liso-Cel; Lupin Seeks New Solosec Indication

November 17, 2020

Manufacturing issue creates setback for Alkermes on much-anticipated therapy that mitigates weight gain.

FDA Updates: COVID-19 Drug Approval, Priority Review for Tagrisso in New Indication

October 25, 2020

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.

FDA Updates: ALKS 3831 Wins Joint Panel Nod; Regeneron, Lilly Seek EUAs for Anti-COVID Antibodies

October 11, 2020

The PDUFA date for Alkermes' combination therapy is November 15, 2020.

Real-World Evidence: A Reality Check

September 29, 2020

Can data mined from EHRs match that from the gold standard, randomized clinical trials?

FDA Updates: Approval to Treat Rare Blood Disorders; Label Change for Benzodiazepines

September 27, 2020

Approval for treatment of HES, update to address addictive nature of benzodiazepines.

FDA Update: Report Claims “Power Grab,” Dems Say Hahn Blocked From Testifying

September 20, 2020

Reports say Azar is asserting control over FDA as vaccine trials near completion, while Hahn is blocked from testifying on COVID-19.